This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n17http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/pubchem-compound/
n30http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/AHFS/
n26http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/kegg-drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/iuphar/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/guide-to-pharmacology/
n28http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/chemspider/
n9http://linked.opendata.cz/resource/drugbank/patent/
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n31http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n23http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/pharmgkb/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00216/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00216
rdf:type
n5:Drug
n5:description
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. [Wikipedia]
n5:dosage
n29:271B5E6A-363D-11E5-9242-09173F13E4C5 n29:271B5E6B-363D-11E5-9242-09173F13E4C5 n29:271B5E68-363D-11E5-9242-09173F13E4C5 n29:271B5E69-363D-11E5-9242-09173F13E4C5
n5:group
approved investigational
n5:halfLife
The terminal elimination half-life of eletriptan is approximately 4 hours.
n5:indication
For the acute treatment of migraine with or without aura in adults.
n5:manufacturer
n26:271B5E63-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00216 n28:DB00216
dcterms:title
Eletriptan
adms:identifier
n11:70379 n12:DB00216 n13:50922 n14:40 n15:D01973 n16:40 n17:77993 n18:46506380 n19:0049-2340-05 n20:PA134687947 n24:Eletriptan
n5:mechanismOfAction
Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. Eletriptan has no significant affinity or pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. Two theories have been proposed to explain the efficacy of 5-HT receptor agonists in migraine. One theory suggests that activation of 5-HT1 receptors located on intracranial blood vessels, including those on the arteriovenous anastomoses, leads to vasoconstriction, which is correlated with the relief of migraine headache. The other hypothesis suggests that activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.
n5:packager
n26:271B5E62-363D-11E5-9242-09173F13E4C5 n26:271B5E60-363D-11E5-9242-09173F13E4C5 n26:271B5E61-363D-11E5-9242-09173F13E4C5 n26:271B5E5E-363D-11E5-9242-09173F13E4C5 n26:271B5E5F-363D-11E5-9242-09173F13E4C5
n5:patent
n9:6110940 n9:5545644 n9:2198599 n9:2352392
n5:synonym
Eletriptanum
n5:toxicity
Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.
n5:volumeOfDistribution
* 138 L
n7:hasAHFSCode
n8:28-32-28
n5:foodInteraction
Exposure to the product (area below curve) and maximum concentrations are increased when product is taken with a high-fat meal.
n5:proteinBinding
Plasma protein binding is moderate and approximately 85%.
n5:salt
n5:synthesisReference
Ronald Ogilvie, "Process for the preparation of eletriptan." U.S. Patent US20050059828, issued March 17, 2005.
foaf:page
n23:rel1663.shtml n30:relpax.htm n31:eletriptan.html
n5:IUPAC-Name
n6:271B5E70-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5E76-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5E75-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5E72-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5E73-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5E74-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5E86-363D-11E5-9242-09173F13E4C5 n6:271B5E6E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5E87-363D-11E5-9242-09173F13E4C5 n6:271B5E6C-363D-11E5-9242-09173F13E4C5 n6:271B5E6F-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5E6D-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n27:N02CC06
n5:H-Bond-Acceptor-Count
n6:271B5E7C-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5E7D-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5E77-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5E78-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5E7A-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5E79-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5E7B-363D-11E5-9242-09173F13E4C5
n5:absorption
Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
143322-58-1
n5:category
n5:clearance
* Renal cl=3.9 L/h
n5:containedIn
n21:271B5E67-363D-11E5-9242-09173F13E4C5 n21:271B5E65-363D-11E5-9242-09173F13E4C5 n21:271B5E66-363D-11E5-9242-09173F13E4C5 n21:271B5E64-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5E82-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5E84-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5E85-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5E81-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5E80-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5E83-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5E71-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5E7E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5E7F-363D-11E5-9242-09173F13E4C5